Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-17T14:08:17.521Z Has data issue: false hasContentIssue false
  • English
  • Français

Antidepressants in Panic Disorders

Published online by Cambridge University Press:  06 August 2018

M.R. Liebowitz
M.R. Liebowitz*
Affiliation:
Department of Psychiatry, College of Physicians and Surgeons, Columbia University; Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

The efficacy of antidepressants for panic disorders has had major effects on our understanding of the classification, pathophysiology, and treatment of anxiety disorders. Psychiatric practice has also been significantly affected, but important issues remain unresolved, such as the mechanisms of therapeutic effect, optimal duration of therapy to minimise relapse, and the interaction and sequencing of medication with cognitive behavioural treatments.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 46 - 52
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aronson, T.A. (1987) A naturalistic study of imipramine in panic disorder and agoraphobia. American Journal of Psychiatry, 144, 1014–1019.Google Scholar
Ballenger, J.C., Burrows, G.D., Dupont, R.L., et al (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Archives of General Psychiatry, 45, 413–422.Google Scholar
Beck, A.T. & Emery, G. (1985) Anxiety Disorders & Phobias. New York: Basic Books.Google Scholar
Buigues, J. & Vallejo, J. (1987) Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychiatry, 48, 55–59.Google ScholarPubMed
Charney, D.S. & Heninger, G.R. (1986) Serotonin function in panic disorders: the effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Archives of General Psychiatry, 43, 1059–1065.Google Scholar
Charney, D.S., Woods, S.W., Goodman, W.K., et al (1986) Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. Journal of Clinical Psychiatry, 47, 580–586.Google Scholar
Charney, D.S., Woods, S.W., Goodman, W.K., et al (1987) Serotonin function in anxiety: effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology, 92, 14–24.CrossRefGoogle ScholarPubMed
Curtis, G.C., Nesse, O.G. & Ness, R.M. (1982) The dexamethasone suppression test in panic disorder and agoraphobia. American Journal of Psychiatry, 139, 1043–1046.Google ScholarPubMed
Den Boer, J.A. (1988) Serotonergic mechanisms in anxiety disorders: an inquiry into serotonin function in panic disorder. Cip-Gegevens Koninklijke Bibliotheek, Hague (Netherlands).Google Scholar
Den Boer, J.A. & Westenberg, G.M. (1988) Effect of serotonin and noradrenaline uptake inhibitor in panic disorders; a double-blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology, 3, 59–74.CrossRefGoogle ScholarPubMed
Den Boer, J.A., Westenberg, G.M., Kamerbeek, W.D.J., et al (1987) Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology, 2, 21–32.Google Scholar
Evans, L. & Moore, G. (1981) The treatment of phobic anxiety by zimelidine. Acta Psychiatrica Scandinavica, 63, 342–345.Google Scholar
Evans, L., Kenardy, J., Schneider, P., et al (1986) Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks: a double blind comparison of zimelidine, imipramine and placebo. Acta Psychiatrica Scandinavica, 73, 49–53.Google Scholar
Fava, G.A., Grandi, S. & Canestrari, R. (1988) Prodromal symptoms in panic disorder with agoraphobia. American Journal of Psychiatry, 145, 1564–1567.Google Scholar
Fyer, A.J. & Sandberg, D. (1988) Pharmacologic treatment of panic disorder. In Review of Psychiatry (eds Frances, A.J. & Hales, R.E.). Washington DC: American Psychiatric Press.Google Scholar
Garakani, H.Z.C. & Klein, D.F. (1984) Treatment of panic disorder with imipramine alone. American Journal of Psychiatry, 141, 446–448.Google Scholar
Gloger, S.G.L., Birmacher, B. & Troudart, T. (1981) Treatment of spontaneous panic attacks with clomipramine. American Journal of Psychiatry, 139, 1215–1217.Google Scholar
Gorman, J.M., Liebowitz, M.R., Fyer, A.J., et al (1987) An open trial of fluoxetine in the treatment of panic attacks. Journal of Clinical Psychopharmacology, 7, 329–332.CrossRefGoogle ScholarPubMed
Gorman, J.M., Liebowitz, M.R., Fyer, A.J., et al (1989) A neuroanatomical hypothesis for panic disorder. American Journal of Psychiatry, 146, 148–161.Google Scholar
Heninger, G.R. & Charney, D.S. (1988) Monoamine receptor systems and anxiety disorders. In The Psychiatric Clinics of North America (eds Winokur, G. & Coryell, W.). Philadelphia: W.B. Saunders.Google Scholar
Johnston, D.G., Troyer, I.E. & Whitsett, S.F. (1988) Clomipramine treatment of agoraphobic women. Archives of General Psychiatry, 45, 453–459.CrossRefGoogle ScholarPubMed
Kahn, R.S. & Van Praag, H.M. (1988) A serotonin hypothesis of panic disorder. Human Psychopharmacology, 3, 285–288.CrossRefGoogle Scholar
Kahn, R.S. & Westerberg, H.G. (1985) L-5-hydroxytryptophan in the treatment of anxiety disorder. Journal of Affective Disorders, 8, 197–200.CrossRefGoogle Scholar
Kahn, R.S., McNair, D.M., Lipman, R.S., et al (1986) Imipramine and chlordiazepoxide in depressive and anxiety disorders. Archives of General Psychiatry, 43, 79–85.Google Scholar
Kahn, R.S., Westenberg, G.M., Verhoeven, W.A., et al (1987) Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. International Clinical Psychopharmacology, 2, 33–41.Google Scholar
Kahn, R.S., Wetzler, S., Van Praag, H.M., et al (1988) Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Research, 25, 101–104.Google Scholar
Kelly, D.G.W., Frommer, E., Mitchell-Heggs, N., et al (1970) Treatment of phobic states with antidepressants: a retrospective study of 246 patients. British Journal of Psychiatry, 116, 387–398.Google Scholar
Klein, D.F. (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 5, 397–408.CrossRefGoogle ScholarPubMed
Klein, D.F. (1988) Nottingham study of neurotic disorder. Lancet, ii, 1015 (letter).Google Scholar
Kockzkas, S.H.G. & Weldin, L. (1981) A pilot study of the effect of the 5-HT uptake inhibitor, zimeldine, on phobic anxiety. Acta Psychiatrica Scandinavica, 63, 328–341.Google Scholar
Liebowitz, M.R. (1985) Imipramine in the treatment of panic disorder and its complications. Psychiatric Clinics of North America, 8, 37–47.Google Scholar
Liebowitz, M.R. (1989) Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of panic disorder. Psychopharmacology Bulletin, 25, 17–20.Google Scholar
Liebowitz, M.R. & Klein, D.F. (1981) Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatric Clinics of North America, 4, 67–87.Google Scholar
Liebowitz, M.R., Fyer, A.J., Gorman, J.M., et al (1986) Phenelzine in social phobia. Journal of Clinical Psychopharmacology, 6, 93–98.Google Scholar
Liebowitz, M.R., Campeas, R. & Hollander, E. (1987) MAOIs: impact on social behaviour. Psychiatry Research, 22, 89–90.Google Scholar
Liebowitz, M.R., Fyer, A.J., Gorman, J.M., et al (1988a) Tricyclic therapy of the DSM—III anxiety disorders: a review with implications for further research. Journal of Psychiatric Research, 22, 7–31.Google Scholar
Liebowitz, M.R., Gorman, J.M., Fyer, A.J., et al (1988b) Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry, 49, 252–257.Google Scholar
Liebowitz, M.R., Quitkin, F.M., Stewart, J.W., et al (1988c) Antidepressant specificity in atypical depression. Archives of General Psychiatry, 45, 129–137.CrossRefGoogle ScholarPubMed
Lydiard, R.B. (1987) Desipramine in agoraphobia with panic attacks: an open fixed-dose study. Journal of Clinical Psychopharmacology, 7, 258–260.Google Scholar
Marks, I.M., Gray, S., Cohen, D., et al (1983) Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Archives of General Psychiatry, 40, 153–162.CrossRefGoogle ScholarPubMed
Mavissakalian, M. & Perel, J. (1985) Imipramine in the treatment of agoraphobia: dose-related relationships. American Journal of Psychiatry, 142, 1032–1036.Google Scholar
Mavissakalian, M. & Michelson, L. (1986) Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry, 47, 117–122.Google Scholar
Noyes, R.J.R., Garvey, M.J., Cook, B., et al (1989). Problems with tricyclic antidepressants in patients with panic disorder: results of a naturalistic follow-up study. Journal of Clinical Psychiatry, 50, 163–169.Google Scholar
Redmond, D.E. (1979) New and old evidence for the involvement of a brain norepinephrine system in anxiety. In Phenomenology and Treatment of Anxiety (eds Fann, W.E., Karacan, I., Podorny, A.O. et al). New York: S.P. Medical & Scientific Books.Google Scholar
Robinson, D.S., Kayser, A., Corcella, J., et al (1985) Panic attacks in outpatients with depression: response to antidepressant treatment. Psychopharmacology Bulletin, 21, 562–567.Google ScholarPubMed
Sargant, W. (1961) Drugs in the treatment of depression. British Medical Journal, i, 225–227.Google Scholar
Sheehan, D.V., Ballenger, J. & Jacobsen, G. (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51–59.Google Scholar
Sheehan, D.V., Davidson, J., Manschreck, T., et al (1983) Lack of efficacy of a new antidepressant (Bupropion) in the treatment of panic disorder with phobias. Journal of Clinical Psychopharmacology, 3, 28–31.Google Scholar
Stefanis, C.N., Alevizos, B., Markianon, B. et al (1988) Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings). Journal of Neural Transmission, 26, 87–95.Google Scholar
Telch, M.J., Agras, W.S., Taylor, C.B., et al (1985) Combined pharmacological and behavioral treatment for agoraphobia. Behavioral Research Therapy, 23, 325–335.Google Scholar
Tyrer, P.M.S. & Shawcross, C. (1988) Monoamine oxidase inhibitors in anxiety disorders. Journal of Psychiatric Research, 22, 87–98.Google Scholar
Tyrer, P.M.S., Kingdon, D., Brothwell, J., et al (1988) The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet, ii, 235–240.Google Scholar
Van Praag, H.M., Lemus, C.Z. & Kahn, R.S. (1987) Hormonal probes of central serotonergic activity: do they really exist? Biological Psychiatry, 22, 86–98.Google Scholar
Versiani, M.M.F.D., Nardi, A.E. & Liebowitz, M.L. (1988) Tranylcypromine in social phobia. Journal of Clinical Psychopharmacology, 8, 279–283.CrossRefGoogle ScholarPubMed
Versiani, M.M.F.D., Nardi, A.E., Liebowitz, M.L., Mundim, F.D., et al (1989) Pharmacotherapy of social phobia (unpublished).Google Scholar
Weissman, M.M. & Merikanga, K.R. (1986) The epidemiology of anxiety and panic disorders. Journal of Clinical Psychiatry, 47, 11–17.Google Scholar
West, E.D. & Dally, P.J. (1959) Effect of iproniazid in depressive syndrome. British Medical Journal, i, 1491–1494.CrossRefGoogle Scholar
Zitrin, C.M., Klein, D.F. & Woerner, M.G. (1980) Treatment of agoraphobia with group exposure in vivo and imipramine. Archives of General Psychiatry, 37, 63–72.Google Scholar
Zitrin, C.M., Klein, D.F. & Woerner, M.G., et al (1983) Treatment of phobias. Archives of General Psychiatry, 40, 125–138.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.